Creative Medical Technology Holdings, Inc. (CELZ): Total Liabilities
$284.9K
As of 2025-12-31
$698.6K
As of 2026-06-30
-55.9%
3-year compound annual growth
-62.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $284.9K | -13.1% | 2026-03-20, Balance as of period end |
| 2024-12-31 | $327.6K | -11.8% | 2026-03-20, Balance as of period end |
| 2023-12-31 | $371.4K | -88.8% | 2025-03-14, Balance as of period end |
| 2022-12-31 | $3.32M | +216.2% | 2024-03-22, Balance as of period end |
| 2021-12-31 | $1.05M | -97.4% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $40.52M | +371.0% | 2021-03-17, Balance as of period end |
| 2019-12-31 | $8.60M | +92.4% | 2021-03-17, Balance as of period end |
| 2018-12-31 | $4.47M | +83.3% | 2020-04-06, Balance as of period end |
| 2017-12-31 | $2.44M | +407.9% | 2019-04-01, Balance as of period end |
| 2016-12-31 | $480.3K | n/a | 2018-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $284.9K | -13.1% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $45.63M | -3.1% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $2.89M | +120.8% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $8.83M | +18.2% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $15.56M | +56.7% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $8.48M | +104.1% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $2.16M | -21.9% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $16.50M | +15.8% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $19.84M | +13.7% |
Compare CELZ, SNTI, ENTX, INMB side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗